<DOC>
	<DOCNO>NCT01434654</DOCNO>
	<brief_summary>Patients infected Human Immunodeficiency Virus ( HIV ) risk brain related complication despite use highly active antiretroviral therapy ( HAART ) . Such complication term HIV neurocognitive disorder ( HAND ) comprise spectrum asymptomatic neurocognitive impairment ( ANI ) , mild cognitive impairment ( MCI ) severe HIV dementia ( HAD ) . Prior HAART approximately 30 % patient advanced HIV disease cognitive impairment; HAART incidence HAND decrease prevalence increase . The reason ongoing development cognitive impairment HAART treat patient clear . They might relate virus induced brain injury prior start HAART , onset separate neurological process , toxicity relate HAART , ongoing viral infection brain . It clear ability different antiretroviral drug penetrate brain varies establish whether difference drug lead different neurological outcome . The investigator propose study HIV infect patient stable HAART 12 months; subdivide group accord brain penetrance drug combination . Patients would undergo neuropsychological assessment MRI brain scan start study 12 month . Differences neuropsychological test MRI would seek treatment group establish whether HAART well CNS penetration associate well outcome few MRI change .</brief_summary>
	<brief_title>Efficacy Neuro-HAART Patients With HIV</brief_title>
	<detailed_description />
	<criteria>HIV positive nadir cluster differentiation 4 ( CD4 ) count &lt; 350 /microlitre ( uL ) Taking HAART CNS Penetration Effectiveness ( CPE ) score either ≤7.0 ≥7.5 1 year . Changes antiretrovirals ( ARVs ) within last 12 month allow long CPE score lead change group Plasma HIV viral load &lt; 50 copy / mL precede 12 month longer Informed consent give participant legally appoint guardian NonHIV relate neurological disorder active CNS opportunistic infection assess full blood count , electrolytes , creatinine , glucose , liver function test , cryptococcal antigen , venereal disease reaction level ( VDRL ) , MRI brain scan cerebrospinal fluid analysis cell count , protein , glucose , culture , VDRL cryptococcal antigen . Psychiatric disorder psychotic axis , current major depression , current substance use disorder assess Study Enrolment Questionnaire Eligibility Severe substance use disorder ( within 12 month study entry ) Active Hepatitis C virus ( HCV ) ( detectable HCV RNA HCV per se cause cognitive impairment ) History loss consciousness &gt; 1 hour Nonproficient English assess `` English second language questionnaire '' Medications know pharmacologically interact ARVs Pregnancy assess urinary pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HAND</keyword>
	<keyword>HIV</keyword>
	<keyword>Neurology</keyword>
	<keyword>Neurocognitive</keyword>
	<keyword>Neuro-HAART</keyword>
	<keyword>HIV Associated Neurocognitive Disorders ( HAND )</keyword>
</DOC>